Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts

• Sponsor: Noveome Biotherapeutics, formerly Stemnion (Industry)
• Overall Status: Terminated
• CT.gov ID: NCT01715012
• Collaborator: (none)
• Enrollment: 1
• Location: 1
• Arms: 2
• Duration (Months): 28.9
• Patients Per Site Per Month: 0

Study Details

Study Description

Brief Summary

This study is a randomized, double blind, placebo controlled trial at a single site. The primary objective is to evaluate the safety of ST266 in diabetic subjects with deep burns. The secondary objectives of this study are to (1) evaluate efficacy of ST266 in healing burns and (2) evaluate whether treatment with ST266 results in less scarring, in subjects with diabetes separately comparing healing of the skin graft and the skin graft donor site using ST266 plus a burn dressing versus placebo and a burn dressing.

Condition or Disease	Intervention/Treatment	Phase
Third Degree Burns; Diabetes	Biological: ST266; Drug: Saline	Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 1 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 2a Randomized, Double Blind, Placebo Controlled, Single-center Study of ST266 Spray in Diabetic Subjects With Deep Burns Managed With Meshed Skin Grafts.
• Study Start Date: Oct 1, 2012
• Actual Primary Completion Date: Jan 1, 2015
• Actual Study Completion Date: Mar 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: ST266 ST266 sprayed to the skin graft and donor site	Biological: ST266; ST266 is applied daily by spray to burn wound and skin graft donor site
Placebo Comparator: Saline Saline (placebo)sprayed to the skin graft and donor site	Drug: Saline; Saline is applied daily by spray to burn wound and skin graft donor site; Other Names: Placebo

Outcome Measures

Primary Outcome Measures

1. Safety [Beginning at enrollment and continuing 12 months after last treatment]

   The primary objective of this study is to evaluate the safety of ST266 in treating burns in diabetic subjects by evaluating adverse events and serious adverse events. Physical examination, hematology, serum chemistry, urinalysis, vital signs, Adverse Event monitoring, and concomitant medications, cytokine and antibody levels will be monitored at baseline and during the study.

Secondary Outcome Measures

1. Healing of skin graft [Up to 2 weeks of treatment]

   Evaluation of ST266 compared with placebo (saline) in treating burns in diabetic subjects by assessing the time to complete healing of the skin graft.

2. Healing of skin graft donor site [Up to 2 weeks of treatment]

   Evaluation of ST266 compared with placebo (saline) in treating burns in diabetic subjects by assessing the healing of the skin graft donor site.

3. Scarring of skin graft [One year following treatment]

   Evaluation of ST266 compared with placebo (saline) in treating burns in diabetic subjects by assessing scarring of the skin graft at six months and one year using a validated scar scale.

4. Scarring of skin graft donor site [One year following treatment]

   Evaluation of ST266 compared with placebo (saline) in treating burns in diabetic subjects by assessing scarring of the skin graft donor site at six months and one year using a validated scar scale.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Signed and dated Institutional Review Board-approved written Informed Consent

• 18 - 75 years of age.

• Thermal or scald burn, either full thickness or deep partial thickness, which in the opinion of the burn surgeon, requires a meshed skin graft to heal.

• Target burn area for treatment equal to or less than three percent total body surface area.

• A skin graft site harvested at 10/1000ths of an inch and a skin graft meshed at 2:1.

• Total Body Surface Area (TBSA) burn of less than or equal to 20 percent total body surface.

• Patient must have a known history of diabetes, or be found to have diabetes at the time of admission, confirmed by a Hemoglobin A1C of greater than 6.5 percent.

• If a woman of child-bearing potential (WOCBP), she and her partner must be willing to employ either a highly effective form of birth control (e.g., implants, injectable medications, a hormone combination oral contraceptive, etc.), sexual abstinence, or a vasectomised partner, in combination with a barrier method, for the entire duration of the study (through study discharge). Male subjects with a WOCBP partner must be willing to use a condom during sexual activity for the entire duration of the study (through study discharge).

• Willing to participate in the clinical study and comply with the requirements of the trial.

Exclusion Criteria:

• Full thickness burns involving tendon, ligament, bone, or joint capsule.

• Burns of the face, neck, palmer surface of the hands and plantar surface of the foot.

• Burn from chemical, electrical or radiation causes.

• Subjects with any immune deficiency including current treatment with corticosteroid medication, chemotherapeutic agents, anti-viral therapy, or concurrent radiation therapy within 30 days of signing the informed consent.

• Active cancer or a history of cancer in the five years prior to signing the informed consent form. (History of basal cell carcinoma is allowed).

• Life expectancy of less than one year.

• Patients requiring care in the Intensive Care Unit.

• Inhalation injury requiring mechanical ventilation.

• Multiple trauma (significant traumatic injury to a solid organ in addition to skin).

• Psychiatric condition or substance abuse which in the Investigator's opinion may pose a threat to subject compliance.

• History of non-compliance with treatment or clinical visit attendance.

• Participation in an investigational trial within 30 days of study entry.

• Women who are pregnant or lactating

• Prisoners

• Acute clinically significant infection (including viral infections) in the six weeks prior to administration of study drug or any clinically significant ongoing chronic infection (excluding fungal infections of the nail beds).

• Evidence or history of skin conditions that would interfere with evaluations.

• Any other uncontrolled concomitant disease, condition, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to individuals in this study or interfere with the interpretation of study data.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The Burn Unit of the Wexner Medical Center at The Ohio State University.	Columbus	Ohio	United States	43210

Sponsors and Collaborators

• Noveome Biotherapeutics, formerly Stemnion

Investigators

• Principal Investigator: Larry Jones, MD, Ohio State University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Noveome Biotherapeutics, formerly Stemnion
• ClinicalTrials.gov Identifier: NCT01715012
• Other Study ID Numbers: ST-03-12
• First Posted: Oct 26, 2012
• Last Update Posted: May 15, 2019
• Last Verified: May 1, 2019

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Noveome Biotherapeutics, formerly Stemnion: Burn; Diabetes; Skin graft; Donor site
• Additional relevant MeSH terms: Burns

Study Results

No Results Posted as of May 15, 2019